1. Home
  2. DOMO vs EDIT Comparison

DOMO vs EDIT Comparison

Compare DOMO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Domo Inc. Class B

DOMO

Domo Inc. Class B

HOLD

Current Price

$2.51

Market Cap

189.3M

Sector

Technology

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.83

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOMO
EDIT
Founded
2010
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.3M
206.0M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
DOMO
EDIT
Price
$2.51
$2.83
Analyst Decision
Buy
Strong Buy
Analyst Count
10
6
Target Price
$11.15
$4.92
AVG Volume (30 Days)
1.6M
1.4M
Earning Date
05-20-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
$317,044,000.00
$31,937,000.00
Revenue This Year
$3.41
N/A
Revenue Next Year
$4.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$2.56
$1.18
52 Week High
$18.49
$4.54

Technical Indicators

Market Signals
Indicator
DOMO
EDIT
Relative Strength Index (RSI) 27.27 65.88
Support Level N/A $2.42
Resistance Level $5.39 $3.17
Average True Range (ATR) 0.23 0.18
MACD -0.02 0.04
Stochastic Oscillator 0.75 85.19

Price Performance

Historical Comparison
DOMO
EDIT

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: